Toll signaling pathway

Across TCGA pan-cancer cohorts, RNA activity of the Toll signaling pathway pathway is associated with patient survival in 19 of 34 cancer lineages. Pathway activity is summarized from the expression of its 11 member genes.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher Toll signaling pathway pathway activity is associated with poorer overall survival. In most high-consensus cancer types, elevated pathway activity shows an unfavorable survival association, although some cancer types, such as UVM and KIRC, show the opposite pattern, with higher activity associated with better survival.

LIHC, UVM, and LGG are the cancer lineages in which this pathway most reproducibly stratifies patient survival.

Pathway-activity survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 represent the survival AUCs for the high- and low-pathway-activity groups, respectively. The group with the lower AUC is interpreted as having poorer survival. The reported p-values are derived from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.385	0.603	<.001	71	view →
UVM	OS	Tertile	II,III,IV	0.806	0.478	.002	55	view →
LGG	OS	Median	All	0.386	0.501	<.001	53	view →
KIRC	OS	Tertile	All	0.920	0.845	<.001	43	view →
PCPG	DFS	Tertile	All	0.546	1.000	<.001	34	view →
KIRP	DFS	Median	II,III,IV	0.621	0.899	.001	28	view →
SCLC	OS	Median	IV	0.959	0.274	.010	25	view →
SKCM	OS	Quartile	All	0.855	0.716	<.001	17	view →
UCEC	DFS	Quartile	All	0.536	0.704	.002	14	view →
COAD	DFS	Quartile	All	0.360	0.677	.017	11	view →
THCA	OS	Median	IV	0.939	0.587	.012	10	view →
DLBC	OS	Tertile	All	0.576	1.000	.036	8	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

GO:0008063–LIHC (OS)

Open the LIHC breakdown →